Managing Agent’s ReportFor the year ended 31 December 2024
The Directors of the managing agent present their report and annual report and accounts for the year ended 31 December 2024.
This annual report and accounts is prepared using the annual basis of accounting as required by Regulation 5 of Statutory Instrument No 1950 of 2008, the Insurance Accounts Directive (Lloyd’s Syndicate and Aggregate Accounts) Regulations 2008 (“the Regulations”).
PRINCIPAL ACTIVITY
Newline Underwriting Management Limited (“NUML”) is the managing agent for Syndicate 1218. The principal activity of the Syndicate is primarily the underwriting of casualty (re)insurance business at Lloyd’s. Syndicate 1218, whose capacity is 100% provided by Newline Corporate Name Limited (“NCNL”), had a capacity of £271.0m for the 2024 year of account (2023: £279.0m, 2022: £238.0m). Syndicate capacity is based on gross premiums net of commissions.
NUML and NCNL are wholly owned subsidiaries of Newline Holdings UK Limited (“NHUKL”), a wholly owned subsidiary of Odyssey Reinsurance Company (“ORC”), part of the Odyssey Group. The ultimate parent is Fairfax Financial Holdings Limited (“Fairfax”), a company incorporated in Canada.
The insurance cover provided by the Syndicate includes the following lines of business:
Affinity and Special Risks
This line of business provides motor-related warranty (extended warranty, collision waiver, tyre and alloy wheel and dent protection), non-motor warranty (brown, white and yellow goods, mobile phones, etc.) credit card enhancement products, Truck, Bus and Motor Physical damage protection and value-driven add-ons (e.g. excess waiver).
Cargo and Specie
This line of business provides physical damage coverage for all types of goods during transit, store, exhibition, consolidation, clearing, distribution, restoration and whilst at manufacturing centres.
Clinical Trials
This line of business protects pharmaceutical and biotech manufacturers and developers as well as clinical research organisations in respect of claims made by research subjects who participated in clinical trials and assert they sustained bodily injury by exposure to the products being tested in the clinical trial.
Crime
This line of business protects financial institutions and other organisations against losses that are discovered during the policy period arising from a variety of dishonest, fraudulent or criminal acts committed by either employees or third parties and includes coverage for robbery, hold-ups, forged documents or computer crime.
Cyber
This line of business protects companies in relation to the financial exposure that arises in the digital and data protection age either on a first party and/or third party basis.
Directors’ and Officers’ (D&O) Liability
This line of business protects directors and officers of commercial entities, financial institutions and other organisations against claims that are made during the policy period seeking to hold directors and officers liable for alleged wrongful acts in their capacity as directors and officers.
Errors and Omissions (E&O)
This line of business protects professional service firms, commercial entities and financial institutions against claims made during the policy period by third parties alleging negligence and seeking to hold the company liable.